Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

This trial compares two treatment approaches for advanced nasopharyngeal cancer (a cancer at the back of the nose and throat): standard induction chemotherapy (gemcitabine + cisplatin) versus a 4-drug combination that adds pembrolizumab (immunotherapy) and bevacizumab (anti-blood vessel drug). **You may be eligible if...** - You are 21 or older with a confirmed diagnosis of non-keratinizing nasopharyngeal carcinoma - Your cancer is at an advanced but locally controlled stage (stage III–IVA) with no distant spread - Your tumor tests positive for Epstein-Barr virus (EBV) - You have measurable disease on imaging scans **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic stage IVB or IVC) - Your cancer is EBV-negative - You have significant heart or organ problems that make the 4-drug combination unsafe Talk to your doctor to see if this trial is right for you.